Neuroone Medical Technologies (NMTC) Q3 2026 earnings summary

Executive summary

• Product revenue for the OneRF Brain Ablation System grew 16% year-over-year to $2.0 million in Q3 FY2026, with orders totaling $2.7 million, a 43% increase year-over-year.

• Gross margins expanded to 59.9% from 53.9% year-over-year, attributed to a favorable product mix.

• Net loss widened to $2.0 million ($0.23 per basic share), compared to $1.5 million in the prior-year quarter.

• Achieved ISO 13485 certification, enabling entry into international markets and signaling compliance with global quality standards.

• Significant clinical milestones include publication of a Mayo Clinic study supporting the OneRF Brain Ablation System's efficacy in patients with neuromodulation devices.

Financial highlights

• Q3 FY2026 product revenue: $2.0 million, up from $1.7 million year-over-year.

• Product gross profit: $1.2 million (59.9% margin), up from $0.9 million (53.9%) year-over-year.

• Operating expenses: $3.6 million, up from $2.8 million year-over-year.

• Net loss: $2.0 million ($0.23 per basic share), compared to $1.5 million ($0.19 per share) year-over-year.

• Cash and cash equivalents: $2.0 million as of June 30, 2026; working capital: $3.7 million; no debt.

Outlook and guidance

• FY2026 recognized revenue expected between $9.2 million and $10.5 million, with $11.2 million in product orders anticipated.

• Backlog expected to be addressed by end of Q4 2026; second manufacturing site qualification underway to increase capacity.

• Continued commercial expansion planned for OneRF Brain Ablation and Trigeminal Nerve Ablation systems in the U.S. and internationally.

• Drug delivery system (StereoCED) anticipated to be ready for investigational human studies by end of September.

• Management expects continued operating losses and significant expenses until higher commercial sales are achieved.